Pd-l1 expression is a prognostic factor in patients with thoracic esophageal cancer treated without adjuvant chemotherapy

32Citations
Citations of this article
29Readers
Mendeley users who have this article in their library.

Abstract

Background/Aim: Programmed death-1 ligand 1 (PD-L1) induces apoptosis of tumor-reactive T-cells, that enables tumors to evade immune defense and thus furthers their growth. Our aim was to determine whether PD-L1 expression status correlates with prognosis in patients with advanced thoracic esophageal squamous cell carcinoma. Patients and Methods: The PD-L1 expression status of 177 patients treated with esophagectomy without preoperative therapy was evaluated immunohistochemically using tissue microarray. We then statistically analyzed the relationships between PD-L1 expression status and clinicopathological features and survival. Results: In patients undergoing surgery alone, PD-L1 expression was significantly positivity associated with a better prognosis. By contrast, there were no significant correlations between PD-L1 expression and clinicopathological features or outcomes in patients treated with surgery plus postoperative adjuvant chemotherapy. Conclusion: PD-L1 positivity in advanced thoracic esophageal squamous cell carcinoma may be predictive of a positive prognosis in patients treated without adjuvant chemotherapy.

Cite

CITATION STYLE

APA

Wakita, A., Motoyama, S., Nanjo, H., Sato, Y., Yoshino, K., Sasaki, T., … Minamiya, Y. (2017). Pd-l1 expression is a prognostic factor in patients with thoracic esophageal cancer treated without adjuvant chemotherapy. Anticancer Research, 37(3), 1433–1441. https://doi.org/10.21873/anticanres.11467

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free